Classes
- Internal Medicine - SE +1B00073 | First Faculty of Medicine
- Internal Medicine - Hematology +1B80307 | First Faculty of Medicine
- Internal Medicine Practice before State Examination +1B81056 | First Faculty of Medicine
- Review of Internal Diseases 1B00341 | First Faculty of Medicine
- Ultrasonographic and Endoscopic TechnologyB00816 | First Faculty of Medicine
- Laboratory Methods in Hematology - Diagnostic Tool and Translation´s Research +1B82551 | First Faculty of Medicine
- Review of Internal Diseases 2B00355 | First Faculty of Medicine
- Review of Internal Medicine - Rehabilitation 1B01536 | First Faculty of Medicine
- News in hematology and blood transfusionB02697 | First Faculty of Medicine
- Diagnosis and therapy in haematology - ethical issuesB02094 | First Faculty of Medicine
Publications
- Cell Death Discovery Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors2025 | First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine
- World Journal of Radiology Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients2025 | First Faculty of Medicine, Second Faculty of Medicine
- Leukemia & Lymphoma The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis2025 | First Faculty of Medicine, Second Faculty of Medicine
- Journal of Clinical Oncology Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA2025 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Expert Review of Molecular Diagnostics Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas2025 | First Faculty of Medicine, Third Faculty of Medicine
- Blood Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial2025 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Bone Marrow Transplantation Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT2025 | First Faculty of Medicine
- Journal of Clinical Oncology Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study2025 | First Faculty of Medicine
- The Lancet: Oncology Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study2025 | Faculty of Medicine in Hradec Králové
- Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration2024 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
Loading network view...
